Breaking News Instant updates and real-time market news.

EGN

Energen

$66.66

0.45 (0.68%)

, XL

XL Group

$55.24

0.27 (0.49%)

17:23
05/15/18
05/15
17:23
05/15/18
17:23

Paulson takes stake in Energen, exits Oasis position

John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of March 31, 2018. Paulson's eight new buys during the first quarter included, by size of position, Energen (EGN), XL Group (XL), Blackhawk (HAWK), and Goldcorp (GG). Paulson exited twelve positions during the quarter, including by size of previous position, Oasis (OAS), Dova (DOVA), Xcerra (XCRA), and Synergy (SGYP). Paulson increased its stake in twelve holdings, including by size of previous position, Viacom (VIAB), Rockwell Collins (COL), Aetna (AET), and Time Warner (TWX). Paulson reduced its stake in twelve holdings, including by size of previous position, Vistra (VST), T-Mobile (TMUS), Mylan (MYL), and Shire (SHPG). Paulson's top holdings as of March 31, in order of size, were SPRD Gold Shares, Mylan, Shire, and Valeant (VRX).

EGN

Energen

$66.66

0.45 (0.68%)

XL

XL Group

$55.24

0.27 (0.49%)

HAWK

Blackhawk

$44.93

-0.025 (-0.06%)

GG

Goldcorp

$13.50

-0.27 (-1.96%)

OAS

Oasis Petroleum

$11.94

0.135 (1.14%)

DOVA

Dova Pharmaceuticals

$26.20

-0.03 (-0.11%)

XCRA

Xcerra

$13.55

-0.18 (-1.31%)

SGYP

Synergy Pharmaceuticals

$1.78

-0.05 (-2.73%)

VIAB

Viacom

$28.27

-0.46 (-1.60%)

COL

Rockwell Collins

$135.27

0.12 (0.09%)

AET

Aetna

$177.07

-0.8 (-0.45%)

TWX

Time Warner

$94.41

0.07 (0.07%)

VST

Vistra Energy

$23.13

0.035 (0.15%)

TMUS

T-Mobile

$56.36

-0.11 (-0.19%)

MYL

Mylan

$38.50

0.25 (0.65%)

SHPG

Shire

$170.72

2.34 (1.39%)

VRX

Valeant

$21.53

0.73 (3.51%)

  • 15

    May

  • 15

    May

  • 15

    May

  • 18

    May

  • 18

    May

  • 18

    May

  • 20

    May

  • 21

    May

  • 29

    May

  • 30

    May

  • 12

    Jun

  • 12

    Jun

  • 18

    Jun

  • 27

    Aug

  • 13

    Nov

  • 21

    Dec

EGN Energen
$66.66

0.45 (0.68%)

05/10/18
BOFA
05/10/18
UPGRADE
BOFA
Buy
Energen upgraded to Buy from Neutral at BofA/Merrill
02/01/18
DBAB
02/01/18
INITIATION
Target $70
DBAB
Buy
Energen initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Nitin Kumar started Energen with a Buy rating and $70 price target.
03/07/18
UBSW
03/07/18
INITIATION
Target $62
UBSW
Neutral
Energen initiated with a Neutral at UBS
UBS analyst Lloyd Byrne started Energen with a Neutral rating and $62 price target.
04/20/18
04/20/18
UPGRADE

Equal Weight
Whiting Petroleum upgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley analyst Drew Venker upgraded Whiting Petroleum (WLL) to Equal Weight from Underweight, citing its "vastly better fundamentals" due to stronger oil prices, well performance and management's embrace of shareholder friendly policies. However, he still sees the risk/reward for Whiting shares as balanced compared to peers. Venker, who added that fundamentals for mid-cap Exploration & Production companies more broadly are the strongest since the downturn began in 2014, called Continental Resources (CLR) his top pick in the space and sees Encana (ECA), Energen (EGN) and Cimarex Energy (XEC) as the other best ways to play the "compelling opportunity" in mid-cap E&P.
XL XL Group
$55.24

0.27 (0.49%)

05/08/18
05/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comcast (CMCSA) downgraded to Neutral from Overweight at Atlantic Equities. 2. Zillow (Z, ZG) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Mahaney citing the recent stock price appreciation. 3. XL Group (XL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Dwelle saying the company's first quarter earnings did not contain any red flags around the sale of the company to AXA (AXAHY), which is on track to close in late second quarter or in the third quarter. 4. Ionis Pharmaceuticals (IONS) downgraded to In Line from Outperform at Evercore ISI with analyst Josh Schimmer citing the safety concerns around volanesorsen discussed in the latest FDA briefing documents, which also "dismantled the company's claims" that the treatment leads to benefits in pancreatis. 5. Sapiens (SPNS) downgraded to Market Perform from Outperform at William Blair with analyst Justin Furby saying consensus estimates for 2019 could be a "too aggressive." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/18
RBCM
05/08/18
DOWNGRADE
RBCM
Sector Perform
XL Group downgraded to Sector Perform from Outperform at RBC Capital
05/08/18
RBCM
05/08/18
DOWNGRADE
Target $57
RBCM
Sector Perform
XL Group downgraded to Sector Perform from Outperform at RBC CapitalAXA
As reported earlier, RBC Capital analyst Mark Dwelle downgraded XL Group (XL) to Sector Perform from Outperform but raised his price target to $57 from $46. The analyst notes that the company's Q1 earnings did not contain any red flags around the sale of the company to AXA (AXAHY), which is on track to close in late Q2 or in Q3. Dwelle adds that his new rating is an indication of low probability of a competitive bidder emerging.
04/02/18
LEHM
04/02/18
DOWNGRADE
Target $58
LEHM
Equal Weight
XL Group downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Jay Gelb downgraded XL Group (XL) to Equal Weight while raising his price target for the shares to $58 from $50 to reflect the takeover by AXA (AXAHY).
HAWK Blackhawk
$44.93

-0.025 (-0.06%)

01/23/18
FANA
01/23/18
DOWNGRADE
FANA
Equal-Weight
Blackhawk downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Lawrence Berlin downgraded Blackhawk Network to Equal-Weight on expectation the planned acquisition at $45.25 per share by Silver Lake and P2 Capital Partners will be completed as announced. The analyst does not expect competing offers for Blackhawk.
01/29/18
JEFF
01/29/18
DOWNGRADE
Target $45
JEFF
Hold
Blackhawk downgraded to Hold from Buy at Jefferies
Jefferies analyst Ramsey El-Assal downgraded Blackhawk Network to Hold and raised his price target for the shares to $45 from $42. The company agreed to be acquired by Silver Lake and P2 Capital Partners in an all-cash transaction for $45.25 per share.
02/01/18
RHCO
02/01/18
DOWNGRADE
Target $45
RHCO
Hold
Blackhawk downgraded to Hold from Buy at SunTrust
SunTrust analyst Oscar Turner downgraded BlackHawk to Hold from Buy and raised his price target to $45 from $43 after the recent buyout announcement by Silver Lake / P2 Capital, saying the higher bid is unlikely because of a "limited universe of strategic bidders" and limited visibility for the company's financial performance.
04/06/18
WELS
04/06/18
DOWNGRADE
WELS
Market Perform
Blackhawk downgraded to Market Perform from Outperform at Wells Fargo
GG Goldcorp
$13.50

-0.27 (-1.96%)

11/30/17
SBSH
11/30/17
DOWNGRADE
Target $13
SBSH
Sell
Barrick Gold downgraded to Sell from Buy at Citi
Citi analyst Alexander Hacking double downgraded Barrick Gold (ABX) to Sell from Buy and cut his price target for the shares to $13 from $20. The analyst cites the company's operating issues and potential for an upcoming reinvestment cycle. He remains "neutral to cautious" on the gold sector heading into 2018. Hacking this morning also upgraded Goldcorp (GG) to Buy and Agnico Eagle (AEM) to Neutral.
01/15/18
FBCO
01/15/18
UPGRADE
Target $19
FBCO
Outperform
Goldcorp upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Anita Soni upgraded Goldcorp to Outperform and raised her price target for the shares to $19 from $15.50. The shares closed Friday up 45c, or 3%, to $14.35. Soni sees Goldcorp posting "attractive" growth over the next two years and believes its analyst day on January 16 will serve as a positive catalyst for the shares. The analyst views the company's valuation as attractive relative to peers.
11/30/17
SBSH
11/30/17
UPGRADE
Target $16
SBSH
Buy
Goldcorp upgraded to Buy from Neutral at Citi
Citi analyst Alexander Hacking upgraded Goldcorp to Buy and raised his price target for the shares to $16 from $15. The multi-year underperformance of the shares has reset investor expectations and "opened up value," Hacking tells investors i a research note. The analyst remains "neutral to cautious" on the gold sector heading into 2018.
04/23/18
ADAM
04/23/18
UPGRADE
ADAM
Buy
Goldcorp upgraded to Buy from Hold at Canaccord
OAS Oasis Petroleum
$11.94

0.135 (1.14%)

05/10/18
BOFA
05/10/18
UPGRADE
BOFA
Neutral
Oasis Petroleum upgraded to Neutral from Underperform at BofA/Merrill
04/30/18
JEFF
04/30/18
INITIATION
Target $13
JEFF
Buy
Oasis Petroleum assumed with a Buy at Jefferies
Jefferies analyst Thomas Hughes assumed coverage of Oasis Petroleum with a Buy rating and $13 price target. The shares trading near historically low levels relative to the group creates an attractive opportunity, Hughes tells investors in a research note.
04/23/18
RHCO
04/23/18
DOWNGRADE
Target $9
RHCO
Sell
Oasis Petroleum downgraded to Sell at SunTrust on valuation
As reported earlier, SunTrust analyst Neal Dingmann downgraded Oasis Petroleum to Sell from Hold on valuation as part of his Q1 preview for companies with exposure to the Bakken Basin. Dingmann notes that while the company's core Bakken "acreage represents some of the best in the basin", he sees its Delaware basin program frac spread underperformance requiring the company to "sacrifice high-return Bakken development for Delaware drilling and completion". However, the analyst is positive on Whiting Petroleum (WLL), raising its price target to $60 from $44 and Continental Resources (CLR), raising its price target to $80 from $75, saying the Bakken well economics observed last year make those companies an "attractive alternative" to the Permian.
04/23/18
RHCO
04/23/18
DOWNGRADE
RHCO
Sell
Oasis Petroleum downgraded to Sell from Hold at SunTrust
DOVA Dova Pharmaceuticals
$26.20

-0.03 (-0.11%)

11/28/17
JEFF
11/28/17
NO CHANGE
Target $33
JEFF
Buy
Dova Pharmaceuticals price target raised to $33 from $30 at Jefferies
Jefferies analyst Eun Yang raised her price target for Dova Pharmaceuticals to $33 after avatrombopag received FDA priority review with an action date of May 21, 2018. The analyst sees a higher probability for regulatory success of 95% and potential approval three months earlier than previously thought. She keeps a Buy rating on Dova.
04/26/18
LTCO
04/26/18
INITIATION
Target $65
LTCO
Buy
Dova Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan started Dova Pharmaceuticals with a Buy rating and $65 price target.
09/26/17
09/26/17
UPGRADE
Target $32

Outperform
Dova Pharmaceuticals upgraded to Outperform at Leerink
As previously reported, Leerink analyst Geoffrey Porges upgraded Dova Pharmaceuticals to Outperform from Market Perform after Shionogi announced results from its phase III trial investigating thrombopoietin receptor agonist lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure. The analyst notes that lusutrombopag is from the same class of drugs as Dova's avatrombopag, but is less effective ex-Japan, and believes Dova's avatrombopag has advantage. Porges also raised his price target on Dova's shares to $32 from $24.
09/26/17
LEER
09/26/17
UPGRADE
LEER
Outperform
Dova Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
XCRA Xcerra
$13.55

-0.18 (-1.31%)

05/09/18
NEED
05/09/18
DOWNGRADE
NEED
Hold
Xcerra downgraded to Hold from Buy at Needham
05/09/18
RILY
05/09/18
DOWNGRADE
Target $14
RILY
Neutral
Xcerra downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Craig Ellis downgraded Xcerra (XCRA) to Hold and lowered his price target for the shares to $14 from $15 to reflect the takeover by Cohu (COHU).
05/09/18
DADA
05/09/18
DOWNGRADE
Target $14
DADA
Neutral
Xcerra downgraded to Neutral at DA Davidson as stock approaches deal price
As reported earlier, DA Davidson analyst Thomas Diffely downgraded Xcerra (XCRA) to Neutral from Buy and lowered his price target to $14 from $15. The analyst believes that a bid competitive to that of Cohu (COHU) is unlikely, adding that the stock price is "likely capped" at the current offer. Diffely further notes that this is a "very attractive acquisition", as Xcerra's products are "highly complimentary" to Cohu's portfolio.
05/09/18
NEED
05/09/18
DOWNGRADE
NEED
Hold
Xcerra downgraded to Hold at Needham on acquisition
As reported earlier, Needham analyst Y. Edwin Mok downgraded Xcerra (XCRA) to Hold from Buy after the announcement that it is being acquired by Cohu for $9 per share in cash and 0.21 a share of Cohu (COHU) stock. Mok says there is limited upside from the deal's combined price of $13.92 per share and does not see the possibility of another bidder emerging. While the analyst expects some regulatory scrutiny given the product overlaps of the two companies, he ultimately sees the deal winning approval.
SGYP Synergy Pharmaceuticals
$1.78

-0.05 (-2.73%)

01/25/18
BTIG
01/25/18
NO CHANGE
Target $7
BTIG
Buy
Synergy funding worries may be overdone, says BTIG
BTIG analyst Timothy Chiang noted that Synergy Pharmaceuticals (SGYP) announced that Trulance received expanded FDA approval for IBS-C, which puts it more on par with market leader Linzess from Ironwood (IRWD) and Allergan (AGN). He sees Trulance benefiting from increased payor access and believes the company will have sufficient cash in order to gain access to a second loan tranche of $100M expected by next month, stating that funding worries may be overdone. Chiang keeps a Buy rating and $7 price target on Synergy shares.
01/25/18
WELS
01/25/18
NO CHANGE
WELS
Outperform
Ironwood outlook unchanged after Trulance approval, says Wells Fargo
Wells Fargo analyst David Maris said that Synergy Pharmaceuticals (SGYP) received FDA approval for Trulance for the treatment of irritable bowel syndrome with constipation, to add to the drug's existing approval for chronic idiopathic constipation. Ironwood's (IRWD) Linzess was initially approved in 2012 for both IBS-C and CIC, noted Maris, who said he expected Trulance's approval in IBS-C and is not making any changes to his Ironwood model following the news. He believes Trulance was already being used off label in IBS-C to some degree, but will be watching if the new on-label indication impacts market share, he said. Maris keeps an Outperform rating on Ironwood shares.
01/05/18
OPCO
01/05/18
DOWNGRADE
OPCO
Perform
Synergy Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Derek Archila downgraded Synergy Pharmaceuticals to Perform citing the "nagging capital overhang." The analyst sees the potential for additional dilutive financing in 2018 saying the company may not be able to qualify for the third and fourth tranches of funding from the CRG deal. Any additional equity offerings may require a meaningful discount to the current stock price, Archila tells investors in a research note.
11/14/17
BTIG
11/14/17
NO CHANGE
Target $7
BTIG
Buy
Synergy Pharmaceuticals price target lowered to $7 from $11 at BTIG
BTIG analyst Timothy Chiang lowered his price target on Synergy Pharmaceuticals to $7, saying the revision reflects the potential risk of need for additional equity funding by late 2018/early 2019. Chiang notes that the company may be able to access $100M early next year as part of its loan agreement with CRG LP, but it must meet market cap and Trulance sales minimum requirements. The analyst keeps his Buy rating on Synergy Pharmaceuticals, saying the company is in position to benefit from increased payer access for Trulance in 2018 and the potential for an expanded treatment indication for IBS-C.
VIAB Viacom
$28.27

-0.46 (-1.60%)

05/15/18
SBSH
05/15/18
NO CHANGE
Target $66
SBSH
Buy
Citi drops likelihood of CBS-Viacom merger to 25% from 50%
Citi analyst Jason Bazinet dropped his likelihood of a CBS (CBS), Viacom (VIAB) merger to 25% from 50% after CBS filed a Delaware lawsuit asking for a restraining order to prevent Shari Redstone from interfering with a special CBS board meeting. The analyst now sees a lower chance of CBS acquiring Viacom. As such, he increased his price target for CBS shares to $66 from $61 and lowered his price target for Viacom shares to $29 from $30.
05/07/18
SPHN
05/07/18
NO CHANGE
Target $58
SPHN
Equal Weight
CBS-Viacom deal could work at Class B shareholders' expense, says Stephens
Stifel analyst Kyle Evans contends that CBS (CBS) posted the kind of quarter that should fundamentally separate the company from many media peers. However, he said there is no more clarity following its report on whether its Class A shareholders will push for a combination with Viacom (VIAB) that "undermines Class B holders." Evans lowered his price target on CBS to $58 from $64 and maintains an Equal Weight rating on the stock.
04/03/18
KEYB
04/03/18
NO CHANGE
KEYB
Sector Weight
KeyBanc would likely view Viacom acquisition by CBS favorably
KeyBanc analyst Andy Hargreaves notes that news reports suggest an all-stock offer for Viacom (VIAB) by CBS (CBS) is imminent. The analyst believes this would create earnings growth potential through cost synergies in excess of what CBS standalone is capable of and could increase the likelihood of monetizing Viacom-owned assets through disposition. Hargreaves views the near-term risk/reward on CBS as positive and would likely view a deal favorably. He reiterates a Sector Weight rating on CBS shares.
04/30/18
BARD
04/30/18
NO CHANGE
Target $33
BARD
Neutral
Twitter's new partnerships highlight 'growing relevance,' says Baird
Disney's (DIS) and Viacom's (VIAB) announced live content/streaming partnerships with Twitter (TWTR) highlight Twitter's "growing relevance as a distribution platform," Baird analyst Colin Sebastian tells investors in a research note. He believes the partnerships should provide tailwinds for Twitter's video advertising business. Video accounts for greater than 50% of Twitter ad revenue and is its fastest growing ad format, Sebastian points out. The analyst says Disney and Viacom represent two of the company's biggest partnership wins to-date. He keeps a Neutral rating on Twitter with a $30 price target. The stock closed the trading day up 4.5% to $30.31.
COL Rockwell Collins
$135.27

0.12 (0.09%)

11/08/17
FBCO
11/08/17
DOWNGRADE
Target $140
FBCO
Neutral
Rockwell Collins downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Robert Spingarn downgraded Rockwell Collins (COL) to Neutral citing the pending acquisition by United Technologies (UTX). The analyst raised his price target for the shares to $140 from $133.
01/05/18
BARD
01/05/18
UPGRADE
Target $156
BARD
Outperform
United Technologies upgraded to Outperform from Neutral at Baird
Baird analyst Peter Arment upgraded United Technologies (UTX) to Outperform from Neutral utilizing pro forma earnings of the pending Rockwell Collins (COL) deal and reflecting higher accretion from tax reform. Arment raised his price target to $156 from $121 on United Technologies shares.
01/16/18
WELS
01/16/18
DOWNGRADE
Target $143
WELS
Market Perform
Rockwell Collins downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Sam Pearlstein downgraded Rockwell Collins to Market Perform saying the stock is largely driven by the pending acquisition by United Technologies (UTX). The analyst has a $143 price target for the shares.
01/16/18
01/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Neutral at Macquarie with analyst Laurent Vasilescu citing weaker North America revenues, flat Connected Fitness revenues, international revenues of up 21% year-over-year, gross margin pressure, and higher SG&A assumptions. 2. Verizon (VZ) downgraded to Neutral from Buy at MoffettNathanson. 3. Lockheed Martin (LMT) and Rockwell Collins (COL) were downgraded to Market Perform from Outperform at Wells Fargo. 4. Spirit Airlines (SAVE) downgraded to Hold from Buy at Stifel with analyst Joseph DeNardi saying he believes Spirit will benefit this year from an improving demand and revenue environment, but that its higher revenue risk relative to potential competitive responses to its expected capacity growth is not fully reflected in the stock at current levels. 5. Finisar (FNSR) downgraded to Sell from Neutral at Goldman Sachs with analyst Doug Clark saying risks of oversupply and competition are heating up in the optical component landscape. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AET Aetna
$177.07

-0.8 (-0.45%)

05/01/18
CANT
05/01/18
UPGRADE
CANT
Overweight
Aetna upgraded to Overweight from Neutral at Cantor Fitzgerald
04/17/18
LEER
04/17/18
NO CHANGE
LEER
Amazon, Trump news positive for drug supply chain, distributors, says Leerink
Leerink analyst Ana Gupte sees the dual pronged news flow on Amazon (AMZN) being unlikely to enter the Hospital drug supply chain, and President Trump poised to give a speech on drug pricing and supply chain reform on April 26 as HHS Secretary Alex Azar solicits ideas for pricing reform as positive for both the drug supply chain across PBMs and drug distributors and biopharma manufacturers that have been roiled by fears of margin compression on both these threats. Within her coverage, the analyst views this as positive for UnitedHealth (UNH) with its Optum Rx PBM, Cigna (CI) with its deal to acquire Express Scripts (ESRX), and Aetna (AET) which has inked a deal with CVS (CVS) in part through equity, as well as Anthem (ANTM) with IngenioRx and Humana (HUM) with or without its potential Walmart (WMT) deal that has a sizable mail order operation.
05/02/18
05/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Juniper was (JNPR) upgraded to Buy from Neutral at BofA/Merrill and to Hold from Sell at Deutsche Bank. 2. Aetna (AET) upgraded to Overweight from Neutral at Cantor Fitzgerald with analyst Steven Halper saying he views the risk/reward on shares as "more compelling" following the company's first quarter results. 3. Freeport McMoRan (FCX) upgraded to Outperform from Neutral at CIBC with analyst Oscar Cabrera saying shares have dropped over 20% following the Q1 report, reflecting a worst-case scenario for the Indonesia scenario. 4. Shutterfly (SFLY) upgraded to Neutral from Sell at Goldman Sachs with analyst Christopher Merwin citing the better than expected Q1 report. 5. CommScope (COMM) upgraded to Outperform from Market Perform at Northland with analyst Tim Savageaux saying he believes the company's unique mix of exposure to Tier 1 carrier investment in both fiber optic and 4G/5G wireless infrastructure offers compelling value following the sharp pullback in shares after only a "fairly modest" cut to its EPS expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/02/18
CANT
05/02/18
UPGRADE
Target $202
CANT
Overweight
Cantor upgrades Aetna to Overweight on 'compelling' risk/reward
Cantor Fitzgerald analyst Steven Halper last night upgraded Aetna to Overweight from Neutral with a price target of $202. The stock closed yesterday down 75c to $178.71. The analyst views the risk/reward on shares as "more compelling" following the company's Q1 results.
TWX Time Warner
$94.41

0.07 (0.07%)

05/02/18
BRRR
05/02/18
NO CHANGE
Target $110
BRRR
Outperform
Odds in favor of Time Warner deal closing, says Barrington
Barrington analyst James Goss said he continues to expect the acquisition of Time Warner (TWX) by AT&T (T) to ultimately gain court approval and his Outperform rating in part reflects the significant gap from the AT&T takeout offer. He also sees relatively modest downside risk in the event of the deal being blocked, given the continued fundamental support based on existing Time Warner assets and operations, he tells investors. Goss maintains a $110 price target on Time Warner shares.
04/11/18
JEFF
04/11/18
NO CHANGE
JEFF
T-Mobile, Sprint deal has more hurdles than AT&T, Time Warner, says Jefferies
A horizontal merger between T-Mobile (TMUS) and Sprint (S) poses more significant regulatory hurdles than the contested AT&T (T), Time Warner (TWX) deal does, Jefferies analyst Scott Goldman tells investors in a research note after the Wall Street Journal reported the two companies are again in merger talks. The analyst believes potential regulatory remedies could include meaningful spectrum divestitures. With that said, he thinks the combined company would create "meaningful accretion," with free cash flow per share nearly 30% higher in year three. Using multiple analysis, Goldman thinks T-Mobile shares could be worth more than $88 in a deal scenario. The stock closed yesterday up 3.4% to $63.13. Further, the analyst recommends buying the tower stocks on yesterday's selloff given his view of significant regulatory hurdles for a Sprint, T-Mobile deal. He has Buy ratings on American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC).
03/23/18
WELS
03/23/18
NO CHANGE
Target $40
WELS
Outperform
AT&T price target lowered to $40 from $48 Wells Fargo
Wells Fargo analyst Jennifer Fritzsche lowered her price target for AT&T (T) to $40 from $48 given recent volatility and uncertainty around Time Warner (TWX) path. Nonetheless, the analyst reiterates an Outperform rating on AT&T shares and believes Q1 2018 will represent the second consecutive quarter of positive handset ads for the company.
04/17/18
PIVT
04/17/18
DOWNGRADE
Target $105
PIVT
Hold
Time Warner downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Time Warner (TWX) to Hold and lowered his price target for the shares to $105 from $108. The stock's value is driven by current trading levels of AT&T (T) under a presumption that the sale of the company goes through, Wieser tells investors in a research note.
VST Vistra Energy
$23.13

0.035 (0.15%)

02/23/18
UBSW
02/23/18
INITIATION
Target $21
UBSW
Neutral
Vistra Energy initiated with a Neutral at UBS
UBS analyst Daniel Ford started Vistra Energy (VST) with a Neutral rating and $21 price target. The analyst views the shares as fairly valued without the Dynegy (DYN) deal and prefers shares of NRG Energy (NRG).
03/06/18
UBSW
03/06/18
UPGRADE
Target $27
UBSW
Buy
Vistra Energy upgraded to Buy from Neutral at UBS
UBS analyst Daniel Ford upgraded Vistra Energy (VST) to Buy and raised his price target for the shares to $27 from $21 and after incorporating the Dynegy (DYN) merger into his model. Management indicated that forecast synergies and operational improvements could be increased, which provides more confidence in achievement of the base forecast of $350M, Ford tells investors in a research note.
03/28/18
MACQ
03/28/18
INITIATION
Target $24
MACQ
Outperform
Vistra Energy initiated with an Outperform at Macquarie
Macquarie started Vistra Energy with an Outperform rating and $24 price target.
05/01/18
SBSH
05/01/18
INITIATION
Target $27
SBSH
Buy
Vistra Energy reinstated with a Buy at Citi
Citi analyst Praful Mehta reinstated coverage of Vistra Energy with a Buy rating and raised his price target for the shares to $27 from $22. Vistra is well positioned to benefit from the market tightening in Texas, Mehta tells investors in a research note. He also expects management to start a dividend, which he feels will help attract a stable investor base.
TMUS T-Mobile
$56.36

-0.11 (-0.19%)

05/08/18
RHCO
05/08/18
NO CHANGE
Target $5.5
RHCO
Hold
Sprint price target lowered to $5.50 at SunTrust
SunTrust analyst Greg Miller lowered his price target on Sprint (S) to $5.50 from $6.50 after its mixed Q4 results, with disappointing ARPU and higher capital expenditures weighing on EBITDA guidance. The analyst expects the perception around Sprint's proposed merger with T-Mobile (TMUS) to dominate investor sentiment amid an "increasingly competitive market", but sees little chance of the passage due to regulatory concerns in spite of Sprint's "targeted pitch around 5G and China that could well resonate with regulators and politicians". Miller keeps a Hold rating on Sprint.
05/03/18
STFL
05/03/18
NO CHANGE
STFL
Stifel says Alaska, JetBlue may be targets if 'Big 4' think they can consolidate
Stifel analyst Joseph DeNardi said in a note to investors prior to the open that the proposed merger of Sprint (S) and T-Mobile (TMUS), and the related approval process, is the first major test of the Trump administration's view on consolidation. Depending on how this case plays out, management teams at the "Big 4" airlines would have significant interest in acquiring Alaska Air (ALK) or JetBlue (JBLU) if they think they could be successful in doing so, he contends. He believes the current consensus in the industry is that Alaska will serve as buyer and consolidator within its segment, but should the Big 4 believe that they could be permitted to be buyers, the M&A outlook would likely change, DeNardi tells investors.
05/02/18
OPCO
05/02/18
NO CHANGE
Target $90
OPCO
Outperform
Oppenheimer sees 80% chance of regulatory approval for T-Mobile/Sprint merger
Oppenheimer analyst Timothy Horan sees an 80% chance of regulatory approval for T-Mobile (TMUS)/Sprint (S) merger given pro-consumer/investment/jobs focus that scale drives, but with concessions. The analyst reiterates an Outperform rating and $90 price target on T-Mobile shares.
05/01/18
JEFF
05/01/18
UPGRADE
Target $5.5
JEFF
Hold
Sprint upgraded to Hold from Underperform at Jefferies
Jefferies analyst Scott Goldman upgraded Sprint (S) to Hold raised his price target for the shares to $5.50 from $4.50 following the company's merger agreement with T-Mobile (TMUS). The analyst sees the deal supporting the valuation into the regulatory review.
MYL Mylan
$38.50

0.25 (0.65%)

04/23/18
WELS
04/23/18
NO CHANGE
WELS
Market Perform
Mylan layoffs will led to questions, says Wells Fargo
Wells Fargo analyst David Maris acknowledges press reports that Mylan is laying off approximately 500 employees, or approximately 15% of its employees in Morgantown, Virginia. Investors will have questions when Mylan reports Q1 results about the layoffs and what Mylan means about the need to make the Morgantown plant less complex, Maris tells investors in a research note. He keeps a Market Perform on Mylan shares.
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
04/19/18
WELS
04/19/18
NO CHANGE
WELS
Wells says bottom has not been reached in generics pricing
After Aceto (ACET) cited the continued intense competitive and pricing pressures in the generic industry when withdrawing its guidance last night, and Novartis (NVS) this morning reported that net sales at its generic unit Sandoz dropped 4% in the quarter, Wells Fargo analyst Davis Maris says he's not ready to call the bottom in generics pricing. Those that have are premature, Maris tells investors in a research note titled "Negative Read Throughs For Generics Continue." The Aceto and Sandoz pricing news shows the data continue to be negative for U.S. generic industry pricing, the analyst contends. He sees a negative read-through for companies with large U.S. commodity generic exposure, such as Teva (TEVA) and Mylan (MYL).
SHPG Shire
$170.72

2.34 (1.39%)

04/19/18
WELS
04/19/18
NO CHANGE
WELS
Outperform
Wells says Allergan investors likely 'relieved and confused' by Shire news
Wells Fargo analyst David Maris believes Allergan (AGN) investors will be "both relieved and confused" by the company's announcement that it was considering a bid for Shire (SHPG) being following approximately four hours later by another announcement saying that it does not intend to make an offer for Shire. After catching up with Allergan, Maris does not think the turn of events reflects a confusion or flip-flopping, but rather was the result of disclosures required by UK takeover law, and "don't reflect anything other than Allergan being caught at a bad time." He maintains an Outperform rating on Allergan shares.
04/19/18
WELS
04/19/18
NO CHANGE
Target $245
WELS
Outperform
Allergan selloff on potential Shire bid understandable, says Wells Fargo
Wells Fargo analyst David Maris believes the selloff today in shares of Allergan (AGN) on news the company is considering a bid for Shire (SHPG) is understandable. Many believe Allergan was in the process of trimming, not bulking up, Maris tells investors in a research note. He believes that if CNBC's subsequent report is true and Allergan won't be making a bid, the "about-face would be an incredible turn given Allergan's press release came out just a couple hours earlier." Further, the analyst thinks investors are now left wondering what type of disruption another major integration could mean for a company that has already had significant organizational change. Maris has an Outperform rating on Allergan with a $245 price target. The stock in afternoon trading is down 4% to $159.36.
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
04/25/18
RHCO
04/25/18
NO CHANGE
Target $205
RHCO
Buy
Shire price target raised to $205 from $190 at SunTrust
SunTrust analyst John Boris raised his price target on Shire (SHPG) to $205 and kept his Buy rating after an updated merger proposal from Takeda (TKPYY), which has until May 8th to make the final offer. Boris believes the combined stock-and-cash offer of $205 is high enough for Shire shareholders to accept the terms, and other bidders could potentially emerge based on its positive catalysts such as Neuroscience strategic review and LANA August PDUFA.
VRX Valeant
$21.53

0.73 (3.51%)

05/15/18
05/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Outperform from Market Perform at Telsey Advisory. 2. CBS (CBS) upgraded to Outperform from Market Perform at Bernstein with the firm saying it views the probability of a CBS-Viacom (VIAB) re-merger as close to zero, for many years to come. 3. Ulta Beauty (ULTA) upgraded to Outperform from Perform at Oppenheimer with analyst Rupesh Parikh saying he still sees the potential for more gains and outperformance from current levels. 4. Valeant (VRX) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying adjusting individual product growth estimates has made her more constructive on Valeant's turnaround story. 5. Scotts Miracle-Gro (SMG) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying he believes the bottom in the stock price has been reached, leading to its usual "counter seasonal trend of outperformance" given that the stock has outperformed the S&P500 from June to January in the past 11 of 15 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/18
MZHO
05/15/18
UPGRADE
MZHO
Buy
Valeant upgraded to Buy from Neutral at Mizuho
05/14/18
BMOC
05/14/18
NO CHANGE
Target $20
BMOC
Market Perform
Valeant price target raised to $20 from $17 at BMO Capital
BMO Capital analyst Gary Nachman raised his price target on Valeant to $20, saying the company's "impressive" Q1 results demonstrate "good returns" on some of its strategic investments. Nachman also raised his FY18 EPS target to $3.42 from $3.12 to reflect the company's raised FY18 guidance. The analyst keeps his Market Perform rating amid continued uncertainty about sustainability of certain revenue drivers and potential contribution from its "key new product launches".

TODAY'S FREE FLY STORIES

BBRG

Bravo Brio Restaurant

$4.05

(0.00%)

15:30
05/20/18
05/20
15:30
05/20/18
15:30
Conference/Events
Bravo Brio Restaurant to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

JBHT

J.B. Hunt

$126.85

1.06 (0.84%)

18:01
05/18/18
05/18
18:01
05/18/18
18:01
Hot Stocks
J.B. Hunt director Garrison sells 100,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

17:56
05/18/18
05/18
17:56
05/18/18
17:56
Hot Stocks
AstraZeneca confirms FDA approval of Lokelma »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

, XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

17:48
05/18/18
05/18
17:48
05/18/18
17:48
General news
Week ending ETF Scorecard: Energy rallies while Utilities and Real Estate slide »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$78.11

-0.62 (-0.79%)

XLU

Utilities SPDR

$48.97

-0.02 (-0.04%)

IYR

DJ US Real Estate Index Fund

$75.47

0.15 (0.20%)

XLP

Consumer Staples Sector SPDR

$49.53

-0.33 (-0.66%)

XLY

Consumer Discretionary Sector SPDR

$104.87

-0.12 (-0.11%)

XLB

S&P Select Materials SPDR

$59.87

0.09 (0.15%)

XLF

Financial Select Sector

$27.95

-0.255 (-0.90%)

XLV

Health Care Select Sector SPDR

$83.23

0.24 (0.29%)

XLK

Technology Select Sector SPDR

$68.89

-0.28 (-0.40%)

XLI

Industrial Select Sector SPDR

$75.34

0.45 (0.60%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

SLV

iShares Silver Trust

$15.48

-0.005 (-0.03%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

UNG

United States Natural Gas Fund

$23.19

-0.085 (-0.37%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.38

-0.095 (-0.11%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$114.28

0.475 (0.42%)

TLT

iShares 20+ Year Treasury Bond Fund

$117.21

0.98 (0.84%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.76

0.4 (0.40%)

SHY

iShares 1-3 Year Treasury Bond

$83.18

0.05 (0.06%)

IWD

iShares Russell 1000 Value

$122.33

-0.49 (-0.40%)

IWF

iShares Russell 1000 Growth

$141.58

-0.03 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHN

athenahealth

$150.09

0.64 (0.43%)

17:37
05/18/18
05/18
17:37
05/18/18
17:37
Hot Stocks
Janus Henderson reports 11.9% stake in athenahealth, urges for sale process »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 06

    Jun

YGYI

Youngevity International

$3.90

-0.08 (-2.01%)

17:33
05/18/18
05/18
17:33
05/18/18
17:33
Syndicate
Breaking Syndicate news story on Youngevity International »

Youngevity International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTCOY

ZTE Corp.

$0.00

(0.00%)

17:32
05/18/18
05/18
17:32
05/18/18
17:32
Periodicals
Kudlow: ZTE needs to overhaul management to get U.S. reprieve, Bloomberg says »

White House National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

, CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

17:31
05/18/18
05/18
17:31
05/18/18
17:31
Periodicals
Pinnacle Foods hires Evercore Partners to examine alternatives, NY Post says »

Pinnacle Foods (PF) has…

PF

Pinnacle Foods

$63.23

-0.45 (-0.71%)

CAG

Conagra Brands

$37.43

-0.28 (-0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

MYND

MYnd Analytics

$3.28

0.075 (2.34%)

17:25
05/18/18
05/18
17:25
05/18/18
17:25
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INWK

InnerWorkings

$8.71

-0.08 (-0.91%)

17:16
05/18/18
05/18
17:16
05/18/18
17:16
Hot Stocks
InnerWorkings receives Nasdaq non-compliance letter due to late 10-Q filing »

InnerWorkings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMA

ADMA Biologics

$5.46

0.05 (0.92%)

17:05
05/18/18
05/18
17:05
05/18/18
17:05
Syndicate
Breaking Syndicate news story on ADMA Biologics »

ADMA Biologics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

17:04
05/18/18
05/18
17:04
05/18/18
17:04
Hot Stocks
Breaking Hot Stocks news story on Solid Biosciences »

Boxer Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDIT

Editas Medicine

$34.85

-3.14 (-8.27%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Editas Medicine data shows subretinal EDIT-101 injection tolerated in primates »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.57

-0.09 (-0.93%)

17:03
05/18/18
05/18
17:03
05/18/18
17:03
Hot Stocks
Jamba announces expected receipt of Nasdaq letter »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.